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Fungal Keratitis Caused by Candida 
orthopsilosis Successfully Treated 
with Caspofungin
Dear Editor,
Candida orthopsilosis, previously known as a subtype 
of C. parapsilosis, was recently classified as a new strain 
through gene sequencing [1]. This strain is rare in human 
infection and had not been reported as a cause of fungal 
keratitis in Korea. 
The first-line antifungal agent for yeast keratitis is topi-
cal amphotericin B. However, previous studies have shown 
that amphotericin B has poor therapeutic effect in treating 
C. parapsilosis, and voriconazole is considered a good al-
ternative [2]. When voriconazole does not have a therapeu-
tic effect, it is necessary to find another antifungal agent 
with proper ocular penetration and no systemic toxicity.
In this report, we present a rare case of fungal keratitis 
caused by C. orthopsilosis and demonstrate caspofungin 
as a new alternative treatment option in fungal keratitis. 
The institutional review board of Yonsei University Col-
lege of Medicine approved this study (2020-0121-001).
A 61-year-old female with a past history of vitrectomy 
for diabetic retinopathy visited our clinic in December 
2018 for ocular pain and corneal opacity in the right eye. 
She had hypertension and diabetes and had previously 
been using autoserum eyedrops for a corneal abrasion, 
which repeatedly improved and deteriorated on an occa-
sional basis. At the initial examination, her corrected visu-
al acuity was 2 / 100 in the right eye. Through slit-lamp 
examination, a 1.5 × 1.7-mm-sized corneal epi-defect with 
infiltration and hypopyon were noted (Fig. 1A, 1B). A cul-
ture test confirmed the diagnosis of C. orthopsilosis, for 
which an initial treatment of topical voriconazole 1% was 
applied every hour. In the first two weeks of treatment, hy-
popyon and the epi-defect with infiltration were improved 
(Fig. 1C, 1D). An antibiotic sensitivity test demonstrated 
that the strain was highly sensitive to caspofungin, inter-
mediately sensitive to voriconazole, and less sensitive to 
amphotericin B. Thus, the patient’s treatment was changed 
to caspofungin 0.5%. After 1 week of treatment with 
caspofungin, the corneal lesion dramatically improved; it 
was completely healed after 2 months of treatment, result-
ing in only mild corneal opacity (Fig. 1E, 1F). No recur-
rence and ocular toxicity event was reported during the 
follow-up period (Fig. 1G, 1H).  
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Fig. 1. Serial slit-lamp findings of this case study. (A,B) Slit-lamp 
photograph at first visit. Corneal epithelial defect and infiltra-
tion was located in the center of the cornea and hypopyon was 
noted. (C,D) Slit-lamp photograph 4 weeks after treatment of 
voriconazole. Hypopyon and corneal infiltration were slightly 
improved but still remained. (E,F) Slit-lamp photograph 1 week 
after treatment of caspofungin. Corneal infiltration was dramati-
cally improved. (G,H) Slit-lamp photograph 2 months after treat-
ment of caspofungin. Corneal lesion was completely improved, 
remaining mild corneal opacity. Written informed consent was 






Voriconazole is a triazole antifungal agent that inhibits 
fungal ergosterol biosynthesis through inhibition of 14-al-
pha-lanosterol demethylation. In addition, amphotericin B 
is a polyene antifungal agent that binds to ergosterol di-
rectly at the cellular membrane, inducing ergosterol se-
questration. These two agents commonly cause depletion 
of ergosterol, disrupting the cell membrane [3].
The present case demonstrated that voriconazole pre-
vented the spread of corneal infiltration by inhibiting 
growth of the fungus through the mechanism mentioned 
above. However, because voriconazole had only a fungi-
static effect on the strain, it did not completely eradicate 
the strain. Therefore, we assumed that the strain persisted, 
and the lesion remained. 
Caspofungin is an echinocandin antifungal agent active 
against Aspergillus and Candida species. Unlike the anti-
fungal agents mentioned above, it acts on the cell wall and 
inhibits the synthesis of (1,3)-D-glucan, one of the essential 
elements of cell walls, causing apoptosis [4]. Thus, since it 
works selectively on fungal cell walls, which do not exist 
in the human body, it has reduced toxicity in the human 
body and can be expected to have an effect on strains that 
are resistant to azole and polyene antifungal agents. Be-
cause of these benefits, caspofungin is widely used as a 
treatment for systemic fungal infection, although it is not 
yet commonly used as a treatment for ocular infection. 
However, several recent studies have reported the curative 
effects of caspofungin on fungal keratitis, and the use of 
caspofungin as a treatment of fungal keratitis has been in-
creasing [5].
To conclude, we presented a case of fungal keratitis 
caused by C. orthopsilosis, which has not been previously 
reported in South Korea, and confirmed caspofungin as a 
new treatment option in cases of voriconazole-resistant 
fungal keratitis. However, further studies will need to 
demonstrate the drug efficacy and toxicity of caspofungin 
as a treatment of fungal keratitis. 
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